The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

Some four years into Jemperli’s commercial life span, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. Tesaro has filed a lawsuit ...

GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal with Flagship Pioneering. Flagship’s Profound Therapeutics and Quotient ...

Wondering if GSK could be a hidden value opportunity or just another stock riding pharma’s global upswing? You are in the right place for a deep dive into what the numbers really say. GSK’s shares ...

Drugmaker GSK and U.S. biotechnology company AnaptysBio started litigation against one another, with each saying the other party breached a licensing agreement for cancer treatment Jemperli. Tesaro, a ...

GSK’s leadership in respiratory medicine goes beyond science—uniting research, collaboration, and care to transform outcomes for Canadians living with chronic airway diseases. Respiratory diseases ...

GSK (GSK) and LTZ Therapeutics have announced a strategic collaboration aimed at developing novel myeloid-cell engager (MCE) therapies in oncology, leveraging LTZ’s proprietary Myeloid Engager ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Supercomputers will take on superbugs in a new venture between pharmaceutical company GSK and UK scientists to ...